Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Fabio Casciani

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8225-2399; OpenAlex author ID A5016906180. Sources: OpenAlex.

Their work

Papers
23 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
110
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: 8 papers · 2025: 4 papers · 2026: 6 papers

Papers 23

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. Pancreatic cancer surgery in Italy: an updated snapshot from a national multicentre analysis of outcomes by hospital volume. Co-author DOI 10.1007/s13304-026-02813-5↗
  3. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  4. Morphologic Characterization of Pancreatic Ductal Adenocarcinoma following Post-neoadjuvant Pancreatectomy and Clinical Value of Intratumor Heterogeneity. Co-author DOI 10.1097/sla.0000000000006565↗
  5. Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19218-8↗
  6. ASO Visual Abstract: Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19370-1↗
  7. Resection to Exploration Ratios and Associated Outcomes in Patients with Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/sla.0000000000006197↗
  8. Reappraising the Role of Intraoperative Neck Margin Revision in Postneoadjuvant Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Multi-institution… Co-author DOI 10.1097/sla.0000000000006322↗
  9. Expert Judgment Supporting a Bayesian Network to Model the Survival of Pancreatic Cancer Patients. Co-author DOI 10.3390/cancers17020301↗
  10. Surgical and Oncological Outcomes of Minimally Invasive Left Pancreatectomy for Pancreatic Cancer: Robotic vs. Laparoscopic Approach. Co-author DOI 10.3390/curroncol32070376↗
  11. Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2024.2485↗
  12. The Italian registry of families at risk for pancreatic cancer (IRFARPC): implementation and evolution of a national program for pancreatic cancer surveillance… First author DOI 10.1007/s10689-024-00366-3↗
  13. Surveillance of Individuals at High Risk of Developing Pancreatic Cancer: A Prevalence Meta-analysis to Estimate the Rate of Low-yield Surgery. Co-author DOI 10.1097/sla.0000000000006094↗
  14. Cure Probabilities After Resection of Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Analysis of 2554 Patients. Co-author DOI 10.1097/sla.0000000000006166↗
  15. Adjuvant Therapy After Upfront Resection of Resectable Pancreatic Cancer: Patterns of Omission and Use-A Prospective Real-Life Study. Co-author DOI 10.1245/s10434-024-14951-4↗
  16. ASO Author Reflections: Adjuvant Therapy for Resectable Pancreatic Cancer in the Real World-Not as Common as One Might Think. Co-author DOI 10.1245/s10434-024-15014-4↗
  17. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. Co-author DOI 10.14309/ajg.0000000000002546↗
  18. The Difficulty of Detecting Occult Metastases in Patients with Potentially Resectable Pancreatic Cancer: Development and External Validation of a Preoperative … Co-author DOI 10.3390/jcm13061679↗
  19. Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective, Lymphadenectomy Protocol. Co-author DOI 10.1245/s10434-022-11417-3↗
  20. Reappraisal of nodal staging and study of lymph node station involvement in distal pancreatectomy for body-tail pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2020.04.006↗
  21. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2019.2277↗
  22. Pancreatic cancer – What's next? First author DOI 10.1016/j.lpm.2019.02.031↗
  23. Pancreatic Cancer in the Era of Neoadjuvant Therapy: A Narrative Overview. Co-author DOI 10.21614/chirurgia.113.3.307↗

Closest collaborators

The 25 strongest of 110 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giuseppe Malleo · 19 shared papers, 2018–2026 · strength 3.60
  2. Roberto Salvia · 19 shared papers, 2018–2026 · strength 3.49
  3. Salvatore Paiella · 13 shared papers, 2019–2026 · strength 2.58
  4. Gabriella Lionetto · 12 shared papers, 2022–2026 · strength 2.39
  5. Massimo Falconi · 8 shared papers, 2024–2026 · strength 1.55
  6. Alessandro Esposito · 6 shared papers, 2019–2026 · strength 1.14
  7. Claudio Luchini · 6 shared papers, 2020–2026 · strength 1.13
  8. Erica Secchettin · 6 shared papers, 2019–2025 · strength 1.10
  9. Claudio Bassi · 8 shared papers, 2018–2024 · strength 1.06
  10. Giulio Belfiori · 5 shared papers, 2024–2026 · strength 1.01
  11. Stefano Crippa · 5 shared papers, 2024–2026 · strength 1.01
  12. Matteo De Pastena · 4 shared papers, 2024–2026 · strength 0.95
  13. Antonio Pea · 3 shared papers, 2025–2026 · strength 0.73
  14. Aldo Scarpa · 3 shared papers, 2022–2026 · strength 0.58
  15. Lívia Archibugi · 3 shared papers, 2024 · strength 0.53
  16. Gabriele Capurso · 3 shared papers, 2024 · strength 0.53
  17. Riccardo Casadei · 3 shared papers, 2024 · strength 0.49
  18. Claudio Ricci · 3 shared papers, 2024 · strength 0.49
  19. Paolo Riccardo Camisa · 2 shared papers, 2026 · strength 0.46
  20. Stefano Partelli · 2 shared papers, 2026 · strength 0.46
  21. Federico De Stefano · 2 shared papers, 2026 · strength 0.46
  22. Nicolò Pecorelli · 2 shared papers, 2026 · strength 0.46
  23. Laura Maggino · 4 shared papers, 2019–2024 · strength 0.46
  24. Diego Palumbo · 2 shared papers, 2026 · strength 0.46
  25. Domenico Tamburrino · 2 shared papers, 2026 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.